Suspiciously soon after Pfizer (NYSE: PFE) and BioNTech (Nasdaq: BNTX) announced positive Phase III data for their COVID-19 vaccine, Russia’s PR machine has whirred to life.
While Russia has not followed international norms and standards of development, it has moved quickly to register its home grown coronavirus vaccine, claiming the crown of first approval while other countries show little interest in the candidate.
The so-called Sputnik V vaccine was approved by Russia’s own medicines regulator, based on early-stage data, the reliability of which has been called into question.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze